One risk that cannot be ruled out with any biotechs is the product/ medicine not reaching the clinical trial primary/ secondary endpoints and risk that regulatory approvals may not be received or is delayed. There may be opportunities to tweak the products and go back to trials but this would result in additional work/ cost/ loss of confidence from the market.
Even if we have historical efficacy data there is no way to say this risk doesn’t exist. At least that is how I view this and base my investment decision.
The RAC 3-Pillar Trifecta, page-154
-
- There are more pages in this discussion • 271 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
